Bernard A. Fox, Co-founder, President, and CEO of UbiVac, shared a post on LinkedIn:
“Great to be in Manhattan at Weill Cornell Medicine along with many of the world’s top cancer immunotherapy researchers who today presented at the Parker Institute for Cancer Immunotherapy Cancer Vaccine Symposium updates to their efforts to FinishCancer.
Today I’m honored to open the first session with our work on cancer’s DarkGenome-derived DarkMatter cancer antigens—an emerging category with significant therapeutic and commercial potential. This is where UbiVac believes it has the edge over the competition ( Merck , BioNTech SE CureVac , myNEO Therapeutics ).
UbiVac believes it has the first Dark Matter/non-canonical cancer immunotherapy that has been administered to patients and has more than a decade of follow-up safety data. To our knowledge, the competition has not enrolled its first patient. UbiVac has administered DPV-001 to more than 34 patients.
I reviewed the promising data presented last week at SITC2025 by Dr. Rom Leidner who reviewed the two-year follow-up data in HNSCC patients treated with UbiVac’s DPV001 in combination with Incyte’s
Checkpoint inhibition.
These early results are highly encouraging:
- >2× improvement in overall survival (OS) compared to standard-of-care pembrolizumab
- 3× higher response rate in PD-1–naïve patients (56% vs. 19% SOC)
- 33% response rate in patients who previously failed anti–PD-1 therapy—a group with significant unmet need
This difficult-to-treat population is where UbiVac plans to initiate its Phase II trial, representing the next major value inflection point for UbiVac as it prepares to change the way solid cancers are treated.”
More posts featuring Bernard A. Fox.